SUBSCRIBE
SUBSCRIBE

Quoin Pharmaceuticals

IN THE PRESS
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
December 23, 2024
 · 
5 min read
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
December 19, 2024
 · 
5 min read
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
December 18, 2024
 · 
5 min read
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
November 7, 2024
 · 
8 min read
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
November 6, 2024
 · 
6 min read
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
November 1, 2024
 · 
2 min read
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
October 23, 2024
 · 
4 min read
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
September 9, 2024
 · 
3 min read
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
August 8, 2024
 · 
8 min read
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
August 6, 2024
 · 
5 min read
JOBS